reason report
bottom line report financi result street
consensu partial expect base recent narrow adcetri
guidanc strong perform quarter driven higher-than-
expect revenu lower-than-expect expens
provid conserv financi guidanc adcetri sale
guidanc reflect impact potenti label expans
frontlin hodgkin lymphoma hl oper expens associ
pend casc transact exclud frontlin hl management expect
adcetri net sale growth similar mid-to-high teen growth
rate seen last two year suggest adcetri base
busi remain strong key pipelin event includ
close casc acquisit approv adcetri frontlin
advanc hl top-lin phase result frontlin
matur t-cell lymphoma mtcl data present form
earli stage pipelin updat
estim reflect financi result guidanc well
propos casc acquisit maintain op rate
pt base posit view outlook
adcetri label expans activ track note cutan
t-cell lymphoma ctcl one key growth area adcetri
addit continu penetr post-transpl hl
mainten set pdufa date frontlin advanc hl
base result trial report management
reiter guidanc report top-lin phase trial
result front-lin mtcl
pivot phase ii studi enfortumab vedotin ev local advanc
metastat urotheli cancer muc patient post checkpoint inhibitor
cpi therapi appear enrol well updat phase result
present upcom asco-gu confer
confirmatori phase patient popul expect
initi phase ev studi combin cpi on-going
plan pivot phase ii studi tisotumab vedotin tv recurr
metastat cervic cancer remain track initi
addit tv studi cancer expect initi
recent announc agreement acquir casc transact
expect close casc advanc program tucatinib
random global pivot studi tucatinib
metastat breast cancer expect complet enrol
base prior casc guidanc ladiratuzumab vedotin sgn-
continu evalu sever phase studi
compani inform leerink partner llc research
revenu mm ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
triple-neg breast cancer tnbc includ monotherapi
combin cpi upcom confer plan
present updat earli stage preclin clinic pipelin
includ preclin data sea-bcma novel antibodi target b-cell
rate share seattl genet outperform believ antibodi drug conjug
technolog foundat import platform
valid clinic data intern extern candid solid blood cancer
lead product adcetri highli activ agent relaps refractori hodgkin lymphoma
hl express target larg number hematolog cancer beyond hl
combin clinic valid activ agent creat high probability-of-success
label expans opportun current pursu address potenti
us peak opportun adcetri proprietari earli stage pipelin
view becom interest well extern collabor pipelin shown
promis could provid long-term upsid compani antibody-drug conjug
toolbox product engin creat multipl proprietari partner shot
goal compani recent expans treatment modal extern busi
develop activ could offer addit diversif longer term base exampl
two approv adc adcetri kadcyla review avail data adc
believ adc among best valid novel drug develop platform among
like reproduc gener addit success drug generic
agent could difficult
price target base-cas valuat deriv dcf-base
analysi probability-adjust sale adcetri enfortumab vedotin tisotumab vedotin
earli stage pipelin dcf analysi use wacc consist
commerci stage compani coverag
risk valuat seattl genet includ uncertainti size commerci
potenti adcetri clinic risk addit indic still-limit safeti experi
remain regulatori execut risk adcetri pipelin candid
 mm except ep
collabor licens agreement revenu
royalti revenu
bs cf mm
chang
oper
invest
financ
royalti
sec file leerink partner estim
on-going phase ii trial r/r dlbcl addl dev
proprietari pipelin upcom event
matur cell lymphoma frontlin alcl lymphoma
data readout
urotheli cancer solid tumor
on-going pivot phase ii trial urotheli cancer previous treat cpi
urotheli cancer solid tumor
on-going phase ib combin trial cpi metastat urotheli cancer
urotheli cancer solid tumor
initi phase metastat urotheli cancer previous treat cpi
compani report leerink partner research
initi pivot phase ii trial recurrent/metastat cervic cancer
initi addit phase ii trial line metastat cervic cancer tumor type
on-going phase trial breast cancer pt
initi phase ib/ii trial combin tecentriq mtnbc
initi phase ib/ii trial combin keytruda mtnbc
trial hold
dlbcl fl front-lin combin rchop rchp
dlbcl combin rice
preclin data aacr
